MX2019006326A - Derivados de tirosina y composiciones que los comprenden. - Google Patents

Derivados de tirosina y composiciones que los comprenden.

Info

Publication number
MX2019006326A
MX2019006326A MX2019006326A MX2019006326A MX2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A
Authority
MX
Mexico
Prior art keywords
compositions
tyrosine hydroxylase
hydroxylase inhibitor
tyrosine derivatives
subject
Prior art date
Application number
MX2019006326A
Other languages
English (en)
Spanish (es)
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2019006326A publication Critical patent/MX2019006326A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2019006326A 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden. MX2019006326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
MX2019006326A true MX2019006326A (es) 2019-07-12

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006326A MX2019006326A (es) 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden.

Country Status (12)

Country Link
EP (1) EP3548086A1 (enExample)
JP (2) JP2019536783A (enExample)
KR (1) KR20190089191A (enExample)
CN (1) CN110062633A (enExample)
AU (1) AU2017368135A1 (enExample)
BR (1) BR112019011033A2 (enExample)
CA (1) CA3045110A1 (enExample)
EA (1) EA201991305A1 (enExample)
IL (1) IL266840A (enExample)
MX (1) MX2019006326A (enExample)
PH (1) PH12019501186A1 (enExample)
WO (1) WO2018102506A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
MX2021013901A (es) 2019-05-14 2022-04-12 Tyme Inc Composiciones y métodos para el tratamiento del cáncer.
BR112022008704A2 (pt) * 2019-11-07 2022-07-19 In3Bio Ltd Métodos e composições para uso de anticorpos de fator de crescimento em combinação com inibidores direcionados para quinase não tirosina
US20210220312A1 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions And Methods For Modulating Cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005072061A2 (en) * 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
CN101516899B (zh) * 2006-04-19 2016-07-06 得克萨斯大学体系董事会 细胞成像和治疗的组合物和方法
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
NZ721280A (en) * 2012-01-17 2017-08-25 Tyme Inc Pharmaceutical compositions and methods for treating cancer
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
PH12019501186A1 (en) 2020-02-10
BR112019011033A2 (pt) 2019-10-15
CN110062633A (zh) 2019-07-26
CA3045110A1 (en) 2018-06-07
JP2022153587A (ja) 2022-10-12
IL266840A (en) 2019-07-31
AU2017368135A1 (en) 2019-06-13
EA201991305A1 (ru) 2019-10-31
EP3548086A1 (en) 2019-10-09
JP2019536783A (ja) 2019-12-19
WO2018102506A1 (en) 2018-06-07
KR20190089191A (ko) 2019-07-30

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MY199019A (en) Pd-1 antibodies
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
EP4613332A3 (en) Cot modulators and methods of use thereof
TWD173671S (zh) 通訊耳機之部分
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
CR20110553A (es) Terapia complementaria contra el cáncer
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
CA3029459C (en) USE OF A LIGNIN FRACTION AS AN ANTI-PHYTOPATHOGENIC AGENT AND ANTI-PHYTOPATHOGENIC COMPOSITIONS COMPRISING IT
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
MX2021008839A (es) Composiciones aglomerantes y metodos para fabricacion y uso de las mismas.
MX2019013642A (es) Compuestos, composiciones y metodos.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX380547B (es) Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos.